genOway Société anonyme (ENXTPA: ALGEN)
Health Care · Biotechnology · FR
€2.44
-0.81% today · -19.9% 1Y
genOway Société anonyme (ENXTPA: ALGEN) operates in the Biotechnology industry within the Health Care sector. The company is valued at $26.48M and employs 157 people.
Over the last twelve months the share price has lost 19.9%, trading between 2.10 and 3.20.
Tweenvest scores genOway Société anonyme across four factors: quality 72/100, value 69/100, growth 67/100. Its strongest factor is quality.
ALGEN price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $26.48M
- Revenue (TTM)
- $33.58M
- P/E
- —
- EPS
- —
- Dividend yield
- —
- Beta (5Y)
- 0.37
- 52-week high
- €3.20
- 52-week low
- €2.10
- Avg volume (3M)
- —
- Shares outstanding
- 9.22M
- Employees
- 157
- Next earnings
- —
About genOway Société anonyme
genOway S.A. is a global biotechnology enterprise that specializes in the creation, production, commercialization, and distribution of custom genetically engineered mouse, rat, and cell line models. The company develops bespoke mouse models, including knockout (KO) and knock-in (KI) types, along with customized rat models featuring constitutive and conditional KO, point mutation KI, and rapid KI options. They also engineer custom cell lines, offering constitutive KO, point mutation KI, reporter KI, quick KI, and general KI functionalities. In addition to these tailored solutions, genOway provides a comprehensive catalog of established models, such as humanized immune checkpoint mouse models, immunodeficient and reconstituted mouse and rat strains, humanized immune target models, various other pre-designed mouse and rat models, and immune checkpoint catalog cell lines. Serving a diverse range of clients, including pharmaceutical and life science companies as well as academic research institutions, genOway was founded in 1999 and is headquartered in Lyon, France.
- ISIN
- FR0004053510
- Founded
- 1999
- Listed since
- May 7, 2007
- Exchange
- Euronext Paris
- Currency
- EUR
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| AbbVie Inc.NYSE: ABBV | $468.22B | $264.52 | -0.17% |
| Amgen Inc.NasdaqGS: AMGN | $237.52B | $443.84 | +1.03% |
| Gilead Sciences, Inc.NasdaqGS: GILD | $181.18B | $146.74 | +0.42% |
| Vertex Pharmaceuticals IncorporatedNasdaqGS: VRTX | $138.91B | $547.59 | -0.08% |
| Regeneron Pharmaceuticals, Inc.NasdaqGS: REGN | $83.28B | $828.50 | -0.66% |
| argenx SEENXTBR: ARGX | $65.85B | €864.20 | -4.19% |
| Moderna, Inc.NasdaqGS: MRNA | $57.92B | $138.89 | -4.26% |
| CSL LimitedASX: CSL | $57.77B | AU$168.30 | -1.69% |
Figures last refreshed Aug 18, 2026.